In silico drug discovery services market is likely to be worth USD 124 million by 2030{Roots}

Roots Analysis has done a detailed study on “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 290+ page report, which features 120+ figures and 135+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

Key Market Insights
 Over 90 firms are actively involved in providing in silico services for drug discovery of different types of biologics; of these, over 30 players claim to have the capabilities to offer services for all steps of discovery
 Majority of the companies offer structure-based drug design focused on early stage drug discovery of a range of large molecules, including antibodies, proteins and peptides
 Featuring the presence of small-mid sized firms, the in silico service provider landscape is well-distributed across various regions; these players have adopted various business models to cater to the evolving needs of the clients
 Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective in silico-based service portfolios and maintain a competitive edge in this industry
 The integration of novel computational techniques, such as artificial intelligence and cloud-based platforms, with in silico approaches is likely to revolutionize the overall drug discovery process

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com

Leave a Reply

Your email address will not be published. Required fields are marked *

In silico drug discovery services market is likely to be worth USD 124 million by 2030(Roots)

Owing to their cost and time saving potential, in silico tools are widely used in modern pharmacological research; several companies have developed novel tools, which are specifically designed to accelerate and augment the drug discovery process.

Roots Analysis has announced the addition of “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” report to its list of offerings.

Presently, in silico tools / approaches are available for the identification, selection and optimization of pharmacological leads. in fact, the predictive power of such solutions has been demonstrated to enable researchers to bypass the traditional experimental screening of billions of molecules against hundreds of biological targets, thereby, allowing significant reductions in the investment of both time and resources.

To order this 290+ page report, which features 120+ figures and 130+ tables, please visit this -https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

Key Market Insights

Over 90 players currently claim to provide in silico drug discovery services for biologics
More than 70% of these companies are small and mid-sized firms. Further, close to 60% of the CROs engaged in this domain, claim to provide services to both pharmaceutical companies and academic institutes. It is worth mentioning that about 30% of players presently offer end-to-end drug discovery services

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Leave a Reply

Your email address will not be published. Required fields are marked *